CA
NZ
UK
AU
IND
US
NEXGEL, Inc. (NASDAQ:NXGL), a Pennsylvania hydrogel maker, published clinical data on May 19, 2026 showing its laser-treatment patch cut plume concentration by 95.6% during laser hair removal. The finding lands weeks after the company closed a transformative acquisition that formed BIONX Surgical, even as …
Niagen Bioscience, (NASDAQ:NAGE) the healthy-aging company once known as ChromaDex, built a profitable supplement business around its patented NAD+ ingredient, Niagen. Now, through a new pharmaceutical subsidiary, it is chasing something harder: an approved drug for a rare pediatric disease that currently has no …
LifeMD (NASDAQ:LFMD) enters the second half of 2026 leaning almost entirely on telehealth after divesting the WorkSimpli software unit last November. First-quarter results showed record subscriber growth and a resurgent weight-management franchise built around branded GLP-1 partnerships, but marketing spend widened the adjusted EBITDA …
Medicus Pharma Ltd. (NASDAQ:MDCX), an Alberta-incorporated, Pennsylvania-based clinical-stage biotech, is testing a dissolvable microneedle patch loaded with doxorubicin as a non-surgical basal cell carcinoma treatment. Preliminary topline data released in March 2026 from its Phase 2 SKNJCT-003 trial showed encouraging clearance rates in the …
LENSAR, Inc. (NASDAQ:LNSR), maker of the ALLY Robotic Cataract Laser System, closed a first quarter dominated by fallout from a terminated Alcon acquisition rather than pure operating momentum. Total revenue slipped 5% year over year to $13.4 million, yet recurring revenue reached $12.6 million, …
InspireMD, Inc. (NASDAQ:NSPR) built its U.S. commercial pitch on CGuard Prime, a mesh-covered carotid stent granted FDA premarket approval in June 2025. Fifteen months later, the company generated first-quarter revenue growth of 122%, expanded to more than 100 hospitals, and disclosed a trial dataset …
Intelligent Bio Solutions (NASDAQ:INBS) has grown its global customer base past 480 accounts and expects to file its long-awaited FDA 510(k) submission for its fingerprint-based drug screening system in the second half of 2026. With triple-digit gross-margin gains, a small but growing revenue base, …
Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) has spent 2026 stacking oncology assets onto its clinical pipeline while advancing its lead antibody, ENV-105, through two cancer trials. Two proposed acquisitions from Celyn Therapeutics remain unclosed term-sheet transactions, not completed deals, and the company continues to disclose going-concern …
GeoVax Labs, Inc. (NASDAQ:GOVX) has narrowed its clinical-stage pipeline around one catalyst: a pivotal Phase 3 trial for GEO-MVA, its mpox and smallpox vaccine candidate, expected to begin in the second half of 2026. The company's first-quarter 2026 filing, dated May 14, 2026, discloses …
Humacyte, Inc. (NASDAQ:HUMA) has spent 2026 building a case that its bioengineered blood vessel can move beyond trauma surgery into the far larger dialysis-access market. Two Phase 3 studies have now cleared statistical hurdles, and management plans a supplemental filing with the FDA in …
Please wait processing your request...